Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Diasome is a biopharmaceutical company focused on diabetes, obesity, and other cardiometabolic diseases, rather than a SaaS or enterprise software provider. According to the website, the company was founded in 2012 and centers its work on “hepatocyte-directed medicine.” Its goal is to use the Hepatocyte Directed Vesicle (HDV™) platform to deliver active pharmaceutical ingredients to the portal vein–liver region, bringing treatment closer to the body’s natural metabolic regulation mechanisms.
Its core HDV™ platform is described as a first-in-class platform that can shift drug action from peripheral tissues to the liver—the starting point of metabolic regulation—and is compatible with multiple active pharmaceutical ingredients. The pipeline covers three areas: insulin, GLP-1, and serotonin. OPTI-2 Injectable HDV-Rapid Acting Insulin has completed Phase 2b, while HDV-GLP-1 and oral HDV-Serotonin are in the preclinical stage. The text also notes that the company holds 42 patents and has raised Series C funding, though the funding amount is not disclosed.
From a SaaS or enterprise software perspective, the website does not provide any plans, subscription pricing, free trials, account system, permission management, APIs, third-party integrations, cloud deployment, or self-hosting options. It also does not disclose common enterprise procurement information such as data security, privacy compliance, SLA, or customer support channels. As such, it should not be evaluated as a software product, and related ratings are not applicable.
Its strengths lie in a clear R&D focus, a differentiated drug-delivery approach centered on the liver as a metabolic control hub, a relatively clear clinical development path, and the backing of a professional team. The limitations are also clear: the main content is primarily a company and pipeline overview, with no visible commercialized drugs, specific efficacy data, regulatory approval status, or product delivery model for enterprise customers.
Diasome is more relevant to pharmaceutical investors, BD partners, clinical researchers, and professionals in the metabolic disease field than to enterprise software buyers. The site does not disclose information about access from China, payment methods, or local alternatives, so its access status should be considered unknown. If users are looking for SaaS or enterprise software, this website does not fall into that category.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on diasome.com official site.
diasome.com is an United States Health provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach diasome.com directly.